A randomized cross-over study of cryopreserved platelets in prophylactic transfusions of thrombocytopenic patients
- PMID: 37596937
- DOI: 10.1111/trf.17503
A randomized cross-over study of cryopreserved platelets in prophylactic transfusions of thrombocytopenic patients
Abstract
Background: The short shelf-life of liquid-stored platelets (LP) at 20-24°C poses shortage and wastage challenges. Cryopreserved platelets have significantly extended shelf-life, and were safe and efficacious for therapeutic transfusions of bleeding patients in the Afghanistan conflict and phase 2 randomized studies. Although hematology patients account for half of platelets demand, there is no randomized study on prophylactic cryopreserved platelet transfusions in them.
Methods: We performed a phase 1b/2a randomized cross-over study comparing the safety and efficacy of cryopreserved buffy coat-derived pooled platelets (CP) to LP in the prophylactic transfusions of thrombocytopenic hematology patients.
Results: A total of 18 adults were randomly assigned 1:1 to CP and LP for their first thrombocytopenic period (TP) of up to 28-days. A total of 14 crossed over to the other platelet-arm for the second TP. Overall, 17 subjects received 51 CP and 15 received 52 LP. CP-arm had more treatment emergent adverse event (29.4% vs. 13.3% of subjects, 9.8% vs. 3.8% of transfusions) than LP-arm but all were mild. No thromboembolism was observed. Both arms had similar bleeding rates (23.5% vs. 26.7% of subjects) which were all mild. Subjects in CP-arm had lower average corrected count increments than LP-arm (mean [SD] 5.6 [4.20] vs. 22.6 [9.68] ×109 /L at 1-4 h, p < .001; 5.3 [4.84] vs. 18.2 [9.52] ×109 /L at 18-30 h, p < .001). All TEG parameters at 1-4 h and maximum amplitude (MA) at 18-30 h improved from baseline post-CP transfusion (p < .05) though improvements in K-time and MA were lower than LP (p < .05).
Discussion: During shortages, CP may supplement LP in prophylactic transfusions of thrombocytopenic patients.
Keywords: bone; cryopreserved; platelets; prophylactic; subjects; thrombocytopenic.
© 2023 AABB.
References
REFERENCES
-
- Stubbs JR, Shaz BH, Vasallo RR, et al. Expanding the platelet inventory to mitigate the impact of severe shortages. Hematology Am Soc Hematol Educ Program. 2022;424-429:424-429.
-
- Milford EM, Reade MC. Comprehensive review of platelet storage methods for use in the treatment of active hemorrhage. Transfusion. 2016;56:S140-S180.
-
- Noorman F, van Dongen TT, Plat MJ, et al. Transfusion: −80°C frozen blood products are safe and effective in military casualty care. PloS One. 2016;11:e0168401. https://doi.org/10.1371/journal.pone.0168401
-
- Khuri SF, Healey N, MacGregor H, Barnard MR, Szymanski IO, Birjiniuk V, et al. Comparison of the effects of transfusions of cryopreserved and liquid-preserved platelets on hemostasis and blood loss after cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1999;117:172-183.
-
- Reade MC, Marks DC, Bellomo R, Deans R, Faulke DJ, Fraser JF, et al. A randomized, controlled pilot clinical trial of cryopreserved platelets for perioperative surgical bleeding: the CLIP-I trial. Transfusion. 2019;59:2794-2804.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
